ArticleAdvances in therapy2021

Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma.

Xiaohui Zeng et al.PubMed ↗Publisher ↗

No numbers read from the abstract.